The researchers used cryo-electron
tomography to assemble 3D images of the Ebola virus nucleocapsid inside host
cells. Credit: Saphire Lab, La Jolla Institute for Immunology
At this moment, the world has few
tools to combat deadly filoviruses, such as Ebola and Marburg viruses. The only
approved vaccine and antibody treatments protect against just one filovirus
species.
Scientists at La Jolla Institute
for Immunology (LJI) are working to guide the development of new antivirals by
leading some clever enemy reconnaissance. These researchers use high-resolution
imaging techniques to examine a virus's molecular structure—and uncover where a
virus is vulnerable to new therapies.
In a new Cell study, scientists in LJI's Center for Vaccine
Innovation share the first detailed, complete images of a viral structure
called the Ebola virus nucleocapsid. This breakthrough may accelerate the
development of antivirals that target this viral structure to combat several
filoviruses at once.
"A universal antiviral is the
dream for stopping any kind of viral disease," says LJI Staff Scientist
Reika Watanabe, Ph.D. who led the Cell study as a first
author. "This study brings us a step closer to finding a universal
antiviral."
Inspecting the enemy
The Ebola virus relies on its
nucleocapsid structure to protect and replicate its own genetic material inside
host cells—and suppress host cellular immunity. Thanks to the
nucleocapsid, Ebola can turn infected host cells into virus-making factories.
For the study, Watanabe achieved a
first in science—by harnessing an imaging technique called cryo-electron
tomography, she glimpsed Ebola's nucleocapsid structure at work inside actual
infected cells.
At first glance, the Ebola virus nucleocapsid looks like a coiled telephone cord. Watanabe revealed the stages of coiling and compression of the coil. She also discovered that the nucleocapsid's cylindrical shape is made up of three layers. Each layer plays a different role as the virus replicates in host cells. Before LJI's imaging studies, the existence of the outer layer was entirely unknown.
This cross-section of the Ebola virus
nucleocapsid offers a detailed view of the layers that make up its
cylinder-like structure. Credit: Saphire Lab, La Jolla Institute for Immunology
Watanabe's work also shows how this
outer layer is composed, and how it provides a flexible tether between the
nucleocapsid and the viral membrane.
"We found that the core
protein adopts different forms in the distinct layers of the nucleocapsid to
play different roles," says LJI Professor, President & CEO Erica
Ollmann Saphire, Ph.D., MBA, who served as study senior author.
Watanabe's further investigations
revealed how the proteins in these layers make contact with each other during
assembly in host cells—and how the Ebola virus rearranges these proteins when
nucleocapsids help form new viral particles.
"This study solves several
puzzles in the field," says Saphire.
Targeting Ebola virus—and more
As Watanabe explains, targeting the
nucleocapsid spells "game over" for the virus. "If you don't
have a nucleocapsid, nothing can happen. That's the core of the virus,"
she says.
In fact, the Ebola virus
nucleocapsid plays such a critical role in infection that Watanabe suspects the
nucleocapsid's overall structure may have stayed the same as filoviruses
evolved. Scientists call this kind of crucial structural feature "conserved"
when it is shared across related species.
Indeed, all pathogenic filovirus
species known so far, including Ebola and Marburg virus, share a conserved
nucleocapsid structure, says Watanabe. She's now leading further research to
study nucleocapsid assembly more closely in Marburg virus.
Additional authors of the study, "Intracellular Ebola Virus nucleocapsid assembly revealed by in situ cryo-electron tomography," include Dawid Zyla, Diptiben Parekh, Connor Hong, Ying Jones, Sharon L. Schendel, Willian Wan, and Guillaume Castillon.
by La Jolla Institute for
Immunology
Source: Discovery paves the way for antivirals against Ebola virus and its deadly relatives (phys.org)
No comments:
Post a Comment